Adam Walsh
Stock Analyst at Roth MKM
(3.60)
# 2,100
Out of 4,486 analysts
124
Total ratings
45.9%
Success rate
6.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Maintained: Buy | $12 | $2.88 | +316.67% | 9 | Jun 30, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $36 | $24.40 | +47.54% | 2 | Jun 17, 2026 | |
| INSM Insmed | Maintained: Buy | $212 | $112.84 | +87.88% | 21 | Jun 8, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $34.12 | +69.99% | 4 | May 13, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $7.60 | +163.16% | 5 | May 8, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $70 → $82 | $35.87 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $266.97 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Maintained: Buy | $298 | $30.61 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Maintained: Hold | n/a | $94.04 | n/a | 8 | Feb 10, 2020 | |
| KYNB Kyntra Bio | Maintained: Buy | $71 | $7.49 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $25 | $2.23 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $140.85 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $0.569 | n/a | 3 | Nov 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $522.25 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $60.35 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $227.36 | $6.99 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $321.59 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $19.79 | n/a | 2 | May 20, 2015 |
Equillium
Jun 30, 2026
Maintained: Buy
Price Target: $12
Current: $2.88
Upside: +316.67%
BioAge Labs
Jun 17, 2026
Reiterated: Buy
Price Target: $36
Current: $24.40
Upside: +47.54%
Insmed
Jun 8, 2026
Maintained: Buy
Price Target: $212
Current: $112.84
Upside: +87.88%
vTv Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $58
Current: $34.12
Upside: +69.99%
Arcturus Therapeutics Holdings
May 8, 2026
Reiterated: Buy
Price Target: $20
Current: $7.60
Upside: +163.16%
Ultragenyx Pharmaceutical
May 18, 2020
Maintained: Buy
Price Target: $70 → $82
Current: $35.87
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $266.97
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Maintained: Buy
Price Target: $298
Current: $30.61
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Maintained: Hold
Price Target: n/a
Current: $94.04
Upside: n/a
Kyntra Bio
Nov 12, 2019
Maintained: Buy
Price Target: $71
Current: $7.49
Upside: n/a
Jun 25, 2019
Maintained: Buy
Price Target: $36 → $25
Current: $2.23
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $140.85
Upside: n/a
Nov 5, 2018
Maintained: Buy
Price Target: $35
Current: $0.569
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $522.25
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $60.35
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $227.36
Current: $6.99
Upside: n/a
Jun 24, 2015
Maintained: Buy
Price Target: $160
Current: $321.59
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $19.79
Upside: n/a